CR20140095A - AN ANTIGEN-SPECIFIC CA6 CYTOTOXIC CONJUGATE AND METHODS TO USE THE SAME - Google Patents

AN ANTIGEN-SPECIFIC CA6 CYTOTOXIC CONJUGATE AND METHODS TO USE THE SAME

Info

Publication number
CR20140095A
CR20140095A CR20140095A CR20140095A CR20140095A CR 20140095 A CR20140095 A CR 20140095A CR 20140095 A CR20140095 A CR 20140095A CR 20140095 A CR20140095 A CR 20140095A CR 20140095 A CR20140095 A CR 20140095A
Authority
CR
Costa Rica
Prior art keywords
methods
cytotoxic
antigen
specific
same
Prior art date
Application number
CR20140095A
Other languages
Spanish (es)
Inventor
Gillian Payne
Philip Chun
Daniel Tavares
Original Assignee
Immunogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunogen Inc filed Critical Immunogen Inc
Priority to CR20140095A priority Critical patent/CR20140095A/en
Publication of CR20140095A publication Critical patent/CR20140095A/en

Links

Landscapes

  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Se describen conjugados citotóxicos que comprenden un agente de enlace celular y un agente citotóxico, composiciones terapéuticas que comprenden el conjugado, métodos para usar los conjugados en la inhibición del crecimiento celular y el tratamiento de la enfermedad, y un equipo de comprende el conjugado citotóxico en todas las modalidades de la invención. En particular, el agente de enlace celular es un anticuerpo monoclonal, y fragmentos de enlace de epítope del mismo, que reconoce y enlaza el glicótopo CA6. La presente invención también está dirigida a versiones humanizadas o recubiertas de DS6, un anticuerpo monoclonal anti-CA6 murino, y fragmentos de enlace de epítope del mismo.Cytotoxic conjugates comprising a cell binding agent and a cytotoxic agent, therapeutic compositions comprising the conjugate, methods for using the conjugates in the inhibition of cell growth and treatment of the disease, and a kit comprising the cytotoxic conjugate are described in all embodiments of the invention. In particular, the cell binding agent is a monoclonal antibody, and epitope binding fragments thereof, which recognizes and binds the CA6 glycopepo. The present invention is also directed to humanized or coated versions of DS6, a murine anti-CA6 monoclonal antibody, and epitope binding fragments thereof.

CR20140095A 2014-02-26 2014-02-26 AN ANTIGEN-SPECIFIC CA6 CYTOTOXIC CONJUGATE AND METHODS TO USE THE SAME CR20140095A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CR20140095A CR20140095A (en) 2014-02-26 2014-02-26 AN ANTIGEN-SPECIFIC CA6 CYTOTOXIC CONJUGATE AND METHODS TO USE THE SAME

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CR20140095A CR20140095A (en) 2014-02-26 2014-02-26 AN ANTIGEN-SPECIFIC CA6 CYTOTOXIC CONJUGATE AND METHODS TO USE THE SAME

Publications (1)

Publication Number Publication Date
CR20140095A true CR20140095A (en) 2014-03-28

Family

ID=51359547

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20140095A CR20140095A (en) 2014-02-26 2014-02-26 AN ANTIGEN-SPECIFIC CA6 CYTOTOXIC CONJUGATE AND METHODS TO USE THE SAME

Country Status (1)

Country Link
CR (1) CR20140095A (en)

Similar Documents

Publication Publication Date Title
MX2021002970A (en) Proteins binding nkg2d, cd16 and a tumor-associated antigen.
JOP20170004B1 (en) Anti-N3pGlu anti-amyloid beta-peptide antibody and its uses
CR20170200A (en) ANTIBODY-FARMACO CONJUGATES
MX2018012757A (en) Agonistic antibodies that bind human cd40 and uses thereof.
CU24498B1 (en) FACTOR XI ANTIBODIES
EA201892294A1 (en) ANTIBODIES AND COMPOSITIONS AGAINST TIM-3
ECSP088241A (en) AN ANTIGEN-SPECIFIC CA6 CYTOTOXIC CONJUGATE AND METHODS TO USE THE SAME
MX2017014955A (en) T-CELL IMMUNORRECEPTOR UNION AGENTS WITH IG DOMAINS AND INHIBITION REASON BASED ON IMMUNORRECEPTOR TIROSINE (TIGIT) AND USES OF THE SAME.
ECSP18096095A (en) ALPHA-SINUCLEIN ANTIBODIES AND USES OF THEM
GT201200318A (en) ANTIBODIES TO GDF8 HUMAN
MX2018004515A (en) Antibody agents specific for human cd19 and uses thereof.
EA201692100A8 (en) NEW ANTIBODIES AGAINST RNF43 AND METHODS OF THEIR APPLICATION
ECSP066294A (en) AN ANTIGEN-SPECIFIC CA6 CYTOTOXIC CONJUGATE AND METHODS TO USE THE SAME
EP4603508A3 (en) Anti-frizzled antibodies and methods of use
CL2019001749A1 (en) Use of anti-sclerostin antibodies in the treatment of imperfect osteogenesis.
MX2020011027A (en) CONSTRUCTS OF TRIVALENT BISECIFIC ANTIBODIES.
EA201891299A1 (en) THERAPEUTIC ANTIBODIES TO CD9
AR101486A1 (en) ANTIBODIES ANTI PROTEIN SIMILAR TO ANGIOPOYETINA 4 AND METHODS OF USE
MX2020003034A (en) Il-5 antibody, antigen binding fragment thereof, and medical application therefor.
AR101671A1 (en) ANTIBODIES ANTI PROTEIN SIMILAR TO ANGIOPOYETINA-4 (ANGPTL4) AND METHODS OF USE
UY37598A (en) MIMETIC ANTIBODIES OF FGF21 AND USES OF THE SAME
MX2020011377A (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF CHRONIC URTICARIA.
MX2019002566A (en) IMMUNOTHERAPY FOR POLIOMAVIRUSES.
EA202190504A1 (en) METHODS FOR TREATMENT OF PSORIASIS
CR20140095A (en) AN ANTIGEN-SPECIFIC CA6 CYTOTOXIC CONJUGATE AND METHODS TO USE THE SAME